Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program (aSAH-Omics): A Multicenter Clinical and Mechanistic Study

What this Trial Is About

Aneurysmal subarachnoid hemorrhage (aSAH) is a serious brain emergency caused by a ruptured aneurysm, leading to high death and disability rates. Despite improvements in imaging and treatment techniques, many patients face poor outcomes due to complications like delayed cerebral ischemia, pneumonia, and other systemic injuries. These secondary problems greatly affect recovery, but the molecular causes are not yet fully clear. This multicenter study aims to explore the biological reasons behind these complications and recovery differences by combining multi-omics data with clinical information in patients with aSAH. The study collects various biospecimens such as blood, cerebrospinal fluid, urine, and other tissues to analyze genomic, transcriptomic, proteomic, metabolomic, and imaging-related data. Patients who have had their aneurysm treated by microsurgical clipping or endovascular coiling within 72 hours of the hemorrhage are included. This research links molecular data with clinical and imaging results to identify key pathways and biomarkers that relate to secondary brain injury and patient outcomes. Participants will be assessed over time with functional outcomes measured by the Modified Rankin Scale at 3, 6, and 12 months after the hemorrhage. Secondary outcomes include rates of rebleeding, delayed cerebral ischemia, anemia, pneumonia, and deep vein thrombosis within the first 30 days or up to 3 months. Biospecimen collection during hospitalization supports detailed analysis. This observational study involves long-term follow-up to better understand the biological basis of aSAH progression and recovery variability.

Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program